- Home
- WFRD vs AKRO Comparison
WFRD vs AKRO Comparison
Compare WFRD & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WFRD | AKRO |
|---|---|---|
| Founded | 1941 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | WFRD | AKRO |
|---|---|---|
| Price | $76.62 | $54.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $85.67 | $73.56 |
| AVG Volume (30 Days) | 699.7K | ★ 1.7M |
| Earning Date | 10-21-2025 | 11-07-2025 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.52 | N/A |
| Revenue | ★ $4,970,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.84 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $36.74 | $21.34 |
| 52 Week High | $86.64 | $58.40 |
Technical Indicators
Market Signals| Indicator | WFRD | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 66.54 |
| Support Level | $73.55 | $54.22 |
| Resistance Level | $78.04 | $54.70 |
| Average True Range (ATR) | 2.83 | 0.14 |
| MACD | 0.21 | -0.11 |
| Stochastic Oscillator | 82.72 | 64.18 |
Price Performance
Historical ComparisonAbout WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.